This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
4 Sector ETFs & Stocks to Benefit From Hot Inflation
by Sanghamitra Saha
U.S. inflation jumped in March, surpassing expectations primarily due to higher petrol and shelter costs, dashing hopes of a June interest rate cut by the Fed.
3 Sector ETFs & Stocks to Bet on March Jobs Data
by Sanghamitra Saha
The U.S. economy added 303, 000 jobs last month. That data breezed past expectations for 205, 000 job gains, according to FactSet consensus estimates, as quoted on CNBC.
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
4 Best Sector ETFs to Play Now
by Sanghamitra Saha
In the ongoing bull market, tech stocks have mainly driven the rally. However, with the rally expanding over the last few months, indicating a significant enhancement in market breadth.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
by Zacks Equity Research
Sector ETF report for RSPH
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
Should You Be Overwhelmed by Solid Q4 Earnings? ETFs to Play
by Sanghamitra Saha
The Q4 of 2023 earnings season has emerged as a surprising success story. However, the cautionary note is that these gains come after a substantial reduction in earnings forecasts, and the outlook for the future remains uncertain.
5 Sector ETFs to Play for Revenue Growth in Q4
by Sanghamitra Saha
The fourth quarter earnings reporting cycle is ongoing. Though investors' top focus remains on bottom line during an earnings reason, top line probably tells you more about the inherent strength of a company.
3 Sector ETFs & Stocks to Bet on Superb January Jobs Data
by Sanghamitra Saha
The U.S. economy added 353,000 for the month, much better than the Dow Jones estimate for 185,000 (as quoted on CNBC).
ETFs to Buy as Mounjaro Powers Eli Lilly's Q4 Earnings Beat
by Sweta Killa
Eli Lilly and Company (LLY) posted robust fourth-quarter 2023 earnings, beating estimates on both the top and bottom lines driven by strong sales of its diabetes and weight-loss treatments.
Forget Rate Cuts, Buy Top-Ranked Sector ETFs
by Sweta Killa
Powell expressed confidence in the economic growth and jobs market. Amid the strong economy, investors could be well served by ETFs from top-ranked sectors.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Forget About a March Rate Cut: Focus on These 3 Stocks Poised to Rally
by Ethan Feller
Strong jobs data this morning shows just how strong the labor market is limiting the odds of rate cuts
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Bull of the Day: Regeneron Pharmaceuticals (REGN)
by Ethan Feller
The Biotechnology company enjoys a litany of bullish catalysts on the horizon